This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. More information about cookies is available in our privacy policy

Their Fight Is Our Fight

Multiple myeloma doesn’t stand still. Science and innovation can’t, either.1 When new discoveries can transform your MM patients’ lives, Sanofi wants to provide you the information needed to guide those transformations.

hear from experts

Dr. Nina Shah and Dr. Evangelos Terpos discuss progression-free survival (PFS) and minimal residual disease (MRD).

Experts Discuss Relevant Endpoints in Multiple Myeloma Clinical Papers

Watch Dr. Evangelos Terpos and Dr. Nina Shah discuss why both progression-free survival (PFS) and minimal residual disease (MRD) are relevant endpoints to be aware of in clinical trials.

Exploring the True Cost of Multiple Myeloma

Despite more than a decade’s worth of research and data collection in the field of multiple myeloma, there still is a lack of an all-encompassing report and data that reflect the true cost of multiple myeloma. Explore a study highlighting the socioeconomic impact of multiple myeloma as well as the costs of treatments and hospital visits.

Stages of research and data collection to explore the true cost of Multiple Myeloma.

Early Diagnosis and Increased Incidence

As the incidence of multiple myeloma grows globally and most patients inevitably relapse, there is an unmet need to continue to improve outcomes in patients with RRMM.

Stages of research and data collection to explore the true cost of Multiple Myeloma.

Better understand how MRD relates to progression-free survival (PFS) and overall survival (OS).

The Increasing Importance of Minimal Residual Disease (MRD)

Better understand how MRD relates to progression-free survival (PFS) and overall survival (OS).

Helping High-Risk Subgroups With Multiple Myeloma

Learn how the continued underrepresentation of high-risk subgroups in clinical trials affects patient outcomes.

Continued underrepresentation of high-risk subgroups in clinical trials affects the outcome of patients with multiple myeloma.

REFERENCE: 1. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-1076.

211125_SANOFI_LOGO_RGB Copy